Live Breaking News & Updates on Nasdaq Oric

Stay updated with breaking news from Nasdaq oric. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Monaco Asset Management SAM Decreases Stock Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)

Monaco Asset Management SAM trimmed its holdings in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) by 31.5% in the second quarter, HoldingsChannel.com reports. The fund owned 378,222 shares of the company’s stock after selling 173,527 shares during the period. ORIC Pharmaceuticals makes up 0.8% of Monaco Asset Management SAM’s investment portfolio, making the […] ....

United States , Robertw Baird , Virtu Financial , Pharmaceuticals Daily , Pharmaceuticals Trading , Acadian Asset Management , Balyasny Asset Management , Pharmaceuticals Inc , Group One Trading , Monaco Asset Management , Free Report , Asset Management , Get Free Report , Visit Holdingschannel , Oric Pharmaceuticals , Nasdaq Oric , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,

ORIC Pharmaceuticals' (ORIC) Outperform Rating Reaffirmed at Wedbush

Wedbush reissued their outperform rating on shares of ORIC Pharmaceuticals (NASDAQ:ORIC – Free Report) in a research report released on Monday, Benzinga reports. The firm currently has a $14.00 price target on the stock. ORIC has been the topic of a number of other research reports. Robert W. Baird raised their price objective on shares […] ....

United States , Robertw Baird , Ameritas Investment Partners Inc , Pharmaceuticals Company Profile , Royal Bank , Group One Trading , Pharmaceuticals Inc , Acadian Asset Management , Pharmaceuticals Daily , Pharmaceuticals Trading , Free Report , Get Free Report , Investment Partners , Asset Management , Oric Pharmaceuticals , Nasdaq Oric , Reiterated Rating ,

Wedbush Reiterates Outperform Rating for ORIC Pharmaceuticals (NASDAQ:ORIC)

Wedbush restated their outperform rating on shares of ORIC Pharmaceuticals (NASDAQ:ORIC – Free Report) in a research report sent to investors on Monday, Benzinga reports. They currently have a $14.00 price objective on the stock. Several other brokerages have also issued reports on ORIC. Citigroup lifted their price target on ORIC Pharmaceuticals from $8.00 to […] ....

United States , Robertw Baird , Pharmaceuticals Daily , Pharmaceuticals Inc , Pharmaceuticals Trading , Royal Bank , Acadian Asset Management , Pharmaceuticals Company Profile , Group One Trading , Ameritas Investment Partners Inc , Free Report , Get Free Report , Investment Partners , Asset Management , Oric Pharmaceuticals , Nasdaq Oric , Reiterated Rating ,

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Consensus Recommendation of "Buy" from Brokerages

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) has earned an average rating of “Buy” from the seven research firms that are currently covering the stock, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have issued ratings on the stock in […] ....

United States , Robertw Baird , Pharmaceuticals Inc , Group One Trading , Oric Pharmaceuticals Inc , Acadian Asset Management , Pharmaceuticals Daily , Pharmaceuticals Stock Performance , Royal Bank , Ameritas Investment Partners Inc , Get Free Report , Investment Partners , Asset Management , Get Free , Oric Pharmaceuticals , Nasdaq Oric ,